CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 957 enrolled
Drug / intervention
SPH3127 tablet +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05359068
NCT05359068Phase 3Completed
CompareCT.gov

A Multi-center, Randomized, Double-blind, Double-Dummy, Positive Parallel Controlled Study to Evaluate the Efficacy and Safety in Treatment of Mild-moderate Essential Hypertension

Shanghai Pharmaceuticals Holding Co., Ltd·interventional·Posted May 3, 2022·Updated May 7, 2024

In Brief

A Phase 3 clinical trial evaluating SPH3127 tablet and Valsartan for Essential Hypertension. Completed, enrolled 957 participants across 40 sites.

Detailed Summary

The primary aim of the study is to assess the antihypertensive efficacy of SPH3127 in patients with mild to moderate essential hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedMay 3, 2022
Enrollment StartJun 10, 2021
Primary CompletionDec 26, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 4.2 years ago

Interventions

SPH3127 tabletdrug

1 tablet

SPH3127 tabletdrug

2 tablets

SPH3127 tabletdrug

4 tablets

Valsartandrug

1 valsartan capsule

SPH3127 tabletdrug

2 tablets

Valsartandrug

1 valsartan capsule